Prediction of Co-Occurrence of Lewy Body Disease with Alzheimer's Disease

Kenichi Hashiguchi; Ryota Kobayashi; Daichi Morioka; Shinobu Kawakatsu; Kazutaka Sakamoto; Hiroshi Matsuda; Akihito Suzuki

doi:10.3233/ADR-240019

Prediction of Co-Occurrence of Lewy Body Disease with Alzheimer's Disease

J Alzheimers Dis Rep. 2024 Apr 8;8(1):609-614. doi: 10.3233/ADR-240019. eCollection 2024.

Authors

Kenichi Hashiguchi¹, Ryota Kobayashi¹, Daichi Morioka¹, Shinobu Kawakatsu², Kazutaka Sakamoto¹, Hiroshi Matsuda³, Akihito Suzuki¹

Affiliations

¹ Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan.
² Department of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
³ Drug Discovery and Cyclotron Research Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan.

Abstract

Identifying the coexistence of Lewy body (LB) pathology with Alzheimer's disease (AD) in clinical practice is important in the era of anti-amyloid-β antibody therapy. However, few studies have predicted the presence of comorbid LB pathology with AD using indicative biomarkers of dementia with Lewy bodies or by collecting detailed clinical symptoms. We report the clinical progression of a 67-year-old patient diagnosed with AD who developed rapid eye movement sleep disorder-like symptoms and transient visual hallucinations 10 years after AD onset and was considered to have comorbid LB pathology based on imaging indicative biomarkers of dementia with Lewy bodies.

Keywords: Alzheimer’s disease; Lewy bodies; dementia; dopamine transporter; myocardial scintigraphy; rapid eye movement sleep behavior disorder; visual hallucinations.